OncoSil Medical’s strategic radiation therapy with a nuclear medicine focus is in three major and distinct unique advantages
OncoSil Medical’s core technology includes the application of radioactive phosphorus (P32) to patients to control tumour growth. The company has spent many years perfecting the production of uniform micro particles (30 micron) that combine a radioactive material with inert silicon.
